Abstract
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are expected to be critical to further elucidate the missing genetic heritability of Alzheimer’s disease (AD) risk by identifying rare coding and/or noncoding variants that contribute to AD pathogenesis. In the United States, the Alzheimer’s Disease Sequencing Project (ADSP) has taken a leading role in sequencing AD-related samples at scale, with the resultant data being made publicly available to researchers to generate new insights into the genetic etiology of AD. In order to achieve sufficient power, the ADSP has adapted a study design where subsets of larger AD cohorts are collected and sequenced across multiple centers, using a variety of sequencing kits. This approach may lead to variable variant quality across sequencing centers and/or kits. Here, we performed exome-wide and genome-wide association analyses on AD risk using the latest ADSP WES and WGS data releases. We observed that many variants displayed large variation in allele frequencies across sequencing centers/kits and contributed to spurious association signals with AD risk. We also observed that sequencing kit/center adjustment in association models could not fully account for these spurious signals. To address this issue, we designed and implemented novel filters that aim to capture and remove these center/kit-specific artifactual variants. We conclude by deriving a novel, fast, and robust approach to filter variants that represent sequencing center- or kit-related artifacts underlying spurious associations with AD risk in ADSP WES and WGS data. This approach will be important to support future robust genetic association studies on ADSP data, as well as other studies with similar designs.
Author Summary Next generation sequencing data represents a highly valuable resource to uncover rare coding and/or noncoding genetic variants that contribute to Alzheimer’s disease risk. In order to achieve large sample sizes that are required for such data, the Alzheimer’s Disease Sequencing Project (ADSP) has taken the leading role in sequencing Alzheimer’s disease related samples at scale in the United States. The ADSP’s study design however leads to variable variant quality across the involved sequencing centers, necessitating a quality control approach that ensures robust genetic association analyses. Here, we present and validate a rigorous quality control pipeline, where we specifically developed a new strategy to handle inter-center variant quality issues in the ADSP. In doing so, we provide a first glance into exome- and genome-wide associations with Alzheimer’s disease risk using the latest releases of ADSP data (respectively 20.5k and 16.9k individuals). In sum, our pipeline is important to support future robust genetic association studies on ADSP data, as well as other studies with similar design. This in turn will contribute to accelerating Alzheimer’s disease gene discovery and gene-driven therapy development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was provided by the The Iqbal Farrukh & Asad Jamal Fund, the NIH (AG060747 and AG047366, granted to M.D.G, AG066206 and AG066515 granted to Z.H), and the Alzheimer's Association (AARF-20-683984, granted to M.E.B), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant agreement No. 890650, granted to Y.L.G).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants or their caregivers provided written informed consents in the original studies. The current study protocol was granted an exemption by the Stanford Institutional Review Board because the analyses were carried out on 'de-identified, off-the-shelf' data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the discovery analyses are available upon application to: - dbGaP (https://www.ncbi.nlm.nih.gov/gap/) - NIAGADS (https://www.niagads.org/) - LONI (https://ida.loni.usc.edu/) - Synapse (https://www.synapse.org/) - Rush (https://www.radc.rush.edu/) - NACC (https://naccdata.org/)
